Update date
31 Dec 2025
Shareable Research Card
NGEN - NERVGEN PHARMA CORP. Research And Development Expense
This metric view shows NGEN - NERVGEN PHARMA CORP. research and development expense history from SEC company facts.
Use it to verify the latest reported value, compare nearby periods, and jump to a cross-company ranking when a curated insight exists.
- Context
- Latest reported period: 2025
- Latest reported value
- CA$13,907,206
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Values may differ by reporting period and company taxonomy.
Return Loop
Why revisit this metric view
This metric history becomes more useful after the next quarterly or annual filing because the latest reported value, period, and company comparison context can all change.
- Latest source-backed update
- Latest period end 31 Dec 2025
- Why come back
- Return after the next filing to verify whether this metric changed and how it compares with the ranking page.
- Current latest reported period: 2025.
- Latest reported value on this page: CA$13,907,206.
- Save this filer if you want to compare the next reported value with this history.
Metric freshness comes from the latest SEC company fact available for this taxonomy tag and the paired company facts page.
Latest update
Latest update for Research And Development Expense
Latest reported research and development expense: CA$13,907,206. Open the source-backed page to compare this metric with the newest filing-backed context.
Page type
Metric history
Latest period
2025
SEC-backed company facts were refreshed from filings filed on 31 Mar 2026.
Benchmark Context
How Research And Development Expense compares with peers
NERVGEN PHARMA CORP. sits in the upper half of the current research and development expense sample.
Compared with
Compared with 44 companies reporting research and development expense in CAD. This keeps the comparison on the same metric and unit family.
Why this is notable
This is about 4.6x the current sample midpoint. Research And Development Expense is down about 12% versus the comparable prior period.
- Visible rows currently span reported period ends from 31 Dec 2016 to 31 Jan 2026.
- Nearby companies in this sample: Cardiol Therapeutics Inc. and Profound Medical Corp..
- Current sample position: rank #12 of 44 comparable companies.
- Peer rows use the latest valid value per company for this exact metric and compatible units.
Peer comparisons use the same metric and compatible units only. Latest reported periods may differ across companies, so open each company page before drawing conclusions.
Save this filer page
Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.
Financial Metric Page
NERVGEN PHARMA CORP.: Research And Development Expense
Latest period: 2025. Period end: 31 Dec 2025. Units: CAD. Frequency: annual.
Research And Development Expense is reported in company XBRL facts filed with the SEC.
Metric snapshot
- Latest value
- CA$13,907,206
- Coverage range
- 31 Dec 2024 - 31 Dec 2025
- Fact rows
- 2
What this metric tells you
- Shows reported research and development expense over 31 Dec 2024 - 31 Dec 2025.
- Includes year-over-year change points to highlight acceleration or slowdown.
- Built from 2 SEC fact rows for this metric and issuer.
How to read this chart
- Start with the latest point, then compare it with the prior periods to see direction.
- Use annual sequence to compare like-for-like periods.
- Use YoY change bars to separate growth from contraction across matching periods.
Official SEC source
Source: SEC company facts
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Reporting periods may differ by company.
- View financial facts overview
- NERVGEN PHARMA CORP. SEC filings
- Latest 10-Q/10-K hub
- Open SEC company facts
Direct filing link is shown only when a matched SEC filing document is available for this metric context.
Compare This Metric Across Companies
Compare latest available Research And Development Expense levels across SEC-reporting companies, then open each company metric page for SEC-backed verification. Reporting periods may differ by company.
NERVGEN PHARMA CORP. appears at rank #12 in the latest comparison sample.
| Rank | Company | Latest value | Report period | Next step |
|---|---|---|---|---|
| 1 | BRP Inc. (doo) | CA$434,700,000 | Year - 31 Jan 2026 | Open BRP Inc. Research And Development Expense |
| 2 | CAE INC (cae) | CA$123,200,000 | Year - 31 Mar 2025 | Open CAE INC Research And Development Expense |
| 3 | BCE INC (bce) | CA$60,000,000 | Year - 31 Dec 2025 | Open BCE INC Research And Development Expense |
| 4 | CYBIN INC. (help) | CA$54,910,000 | Year - 31 Mar 2025 | Open CYBIN INC. Research And Development Expense |
| 5 | CAMECO CORP (ccj) | CA$38,467,000 | Year - 31 Dec 2025 | Open CAMECO CORP Research And Development Expense |
| 6 | Grace Therapeutics, Inc. (grce) | CA$38,366,000 | Year - 31 Mar 2019 | Open Grace Therapeutics, Inc. Research And Development Expense |
Metric Details
- Metric
- Research And Development Expense (ResearchAndDevelopmentExpense)
- Frequency coverage
- annual
- Taxonomy
- ifrs-full
- Units tracked
- CAD
- History range
- 31 Dec 2024 - 31 Dec 2025
- Facts on this page
- 2
- SEC metric endpoint
- Open SEC company concept
Metric identity
Names, identifiers, and filing context for this profile.
1 identity field
Metric coverage
3 source fields
Source evidence
Original filing metadata and source links for verification.
1 source field
Chart Context
Compare periods with the same frequency first, then use YoY and TTM series to confirm whether changes are structural or one-off.
Research And Development Expense, Annual (CAD)
Research And Development Expense, YoY Annual Change (%)
NERVGEN PHARMA CORP. Annual Research And Development Expense (CAD)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | CA$13,907,206 | -CA$1,903,814 | -12% | 01 Jan 2025 | 31 Dec 2025 | 40-F | 31 Mar 2026 | 2025 | FY |
| 2024 | CA$15,811,020 | 01 Jan 2024 | 31 Dec 2024 | 40-F | 31 Mar 2026 | 2025 | FY |
* marks a reported value that did not pass the local value check.